Torrent Pharmaceuticals to co-market Saroglitazar Mg with Zydus for liver health
Torrent Pharmaceuticals Limited and Zydus Lifesciences Limited announced a significant licensing and supply agreement to co-market Saroglitazar Mg, a drug for treating Non-Alcoholic Steato Hepatitis ... Read More
Zydus and Lupin forge alliance for NAFLD and NASH treatment in India
In a significant move within the pharmaceutical industry, Zydus Lifesciences Limited, renowned for its global lifesciences innovations, and Lupin Limited, a leading global pharma entity, ... Read More
Zydus Lifesciences initiates phase 4 trial for Saroglitazar Mg in NAFLD
Zydus Lifesciences, an Indian life sciences company, has announced the commencement of Phase IV Real World Data Registry trial "EVIDENCES-XI" for Saroglitazar Magnesium (Mg) in ... Read More
Zydus Cadila begins EVIDENCES-X phase 2b NASH trial of Saroglitazar Mg
Zydus Cadila (Cadila Healthcare) has dosed the first patient in the EVIDENCES-X phase 2b clinical trial of Saroglitazar Magnesium (Saroglitazar Mg) in non-alcoholic steatohepatitis (NASH). ... Read More
Poxel wraps up enrollment in DESTINY-1 phase 2 trial for PXL065 in NASH
Poxel, a French biopharma company, has wrapped up patient enrollment for the phase 2 DESTINY-1 clinical trial, which is evaluating PXL065 for the treatment of ... Read More
TERN-201 NASH clinical trial : Terns reports positive results for phase 1 study
TERN-201 NASH clinical trial : Terns Pharmaceuticals said that an ongoing phase 1 trial of its semicarbazide-sensitive amine oxidase (SSAO) inhibitor TERN-201 in non-alcoholic steatohepatitis ... Read More
Viking Therapeutics initiates VOYAGE study for VK2809 in NASH
Viking Therapeutics has initiated the VOYAGE study, a phase 2b clinical trial of its liver-selective thyroid hormone receptor beta agonist VK2809 in patients with biopsy-confirmed ... Read More